World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 5 January 2021
Main ID:  EUCTR2017-000679-10-SK
Date of registration: 02/10/2017
Prospective Registration: Yes
Primary sponsor: Novartis Pharma AG
Public title: Effect on secukinumab on radiographic progression in ankylosing spondylitis as compared to GP2017 (adalimumab biosimilar)
Scientific title: A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis - SURPASS
Date of first enrolment: 24/10/2018
Target sample size: 837
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000679-10
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: yes Other trial design description: Pts know if they receive PR1 or PR2;but they don`t know the dose of PR1 (150 or 300mg) they receive If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 3  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Argentina Australia Belgium Canada Chile Colombia Czech Republic Czechia
Denmark Finland France Germany Greece Israel Japan Korea, Republic of
Mexico Monaco Netherlands Peru Philippines Poland Portugal Romania
Russian Federation Slovakia Spain Taiwan Turkey United Kingdom United States
Contacts
Name: DRA information desk   
Address:  Žižkova 22B SK-811 02 Bratislava Slovakia
Telephone: +421 2 50706116
Email: dra.slovakia@novartis.com
Affiliation:  Novartis Slovakia s.r.o.
Name: DRA information desk   
Address:  Žižkova 22B SK-811 02 Bratislava Slovakia
Telephone: +421 2 50706116
Email: dra.slovakia@novartis.com
Affiliation:  Novartis Slovakia s.r.o.
Key inclusion & exclusion criteria
Inclusion criteria:
- Male or non-pregnant, non-nursing female patients at least 18 years of age.
- Diagnosis of moderate to severe Ankylosing Spondylitis with radiologic evidence (centrally read X-ray) fulfilling the Modified New York criteria for AS despite previous or current NSAID/non biologic DMARD therapy.
- Active AS assessed by total BASDAI = 4 on a scale of 0-10.
- Spinal pain as measured by BASDAI question #2 = 4 (0-10).
- Total back pain as measured by visual analog scale (VAS) = 40 mm (0-100 mm).
- hsCRP = 5mg/L OR presence of at least 1 syndesmophyte on centrally read spinal X-ray.

Other protocol-defined inclusion criteria may apply,
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 753
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 84

Exclusion criteria:
- Patients with total ankylosis of the spine.
- Pregnant or nursing (lactating) women.
- Evidence of ongoing infectious or malignant process.
- Previous exposure to any biologic immunomodulating agent, including those targeting IL-17, IL-17 receptor or TNFa.
- Subjects taking high potency opioid analgesics.
- Previous treatment with any cell-depleting therapies including but not limited to anti-CD20, investigational agents.

Other protocol-defined exclusion criteria may apply,


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Ankylosing spondylitis
MedDRA version: 20.0 Level: PT Classification code 10002556 Term: Ankylosing spondylitis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Intervention(s)

Trade Name: COSENTYX
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: secukinumab
CAS Number: 1229022-83-6
Current Sponsor code: AIN457
Other descriptive name: SECUKINUMAB
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe
Route of administration of the placebo: Subcutaneous use

Trade Name: Hyrimoz
Product Name: adalimumab
Product Code: GP2017
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: ADALIMUMAB
CAS Number: 331731-18-1
Current Sponsor code: GP2017
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 50-

Primary Outcome(s)
Main Objective: To demonstrate the proportion of subjects on secukinumab (150 mg s.c. or 300 mg s.c.) with no radiographic progression as measured by mSASSS at Week 104 is superior to subjects on GP2017 (adalimumab biosimilar 40 mg s.c.).
Primary end point(s): No radiographic progression as measured by modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) for 150 mg sc or 300 mg sc secukinumab versus GP2017)
Secondary Objective: -To demonstrate the change from baseline in mSASSS in subjects on AIN457 (150mg sc or 300mg sc) is superior to GP2017 at W104
-To demonstrate the proportion of subjects with a syndesmophyte at baseline with no new syndesmophytes at W104 on AIN457 (150mg sc or 300mg sc) is superior to GP2017
-To evaluate the Berlin SI joint edema score in subjects on AIN457 (150mg sc and 300mg sc) at W104 versus GP2017 (in a subset of subjects at selected sites)
-To evaluate the ASspiMRI-a Berlin modification score in subjects on AIN457 (150mg sc or 300mg sc) at W104 versus GP2017 (in a subset of subjects at selected sites)
-To evaluate ASAS20 response, ASAS40 response, ASAS partial remission and ASDAS inactive disease in subjects on AIn457 150mg sc compared to AIN457 300mg sc at W104
-Overall safety and tolerability of AIN457
Timepoint(s) of evaluation of this end point: 104 weeks
Secondary Outcome(s)
Secondary end point(s): - Change from baseline in modified Stoke Ankylosing Spondylitis Spine Score (mSASSS).
- No new syndesmophyte as measured by mSASSS.
- Assessment of SpondyloArthritis International Society 20 (ASAS20).
- ASAS 40.
- ASAS partial remission.
- Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease.
- Berlin sacroiliac (SI) joint edema score.
- Ankylosing Spondylitis Spine Magnetic Resonance Imaging - activity (ASspiMRI-a) Berlin modification score.
Timepoint(s) of evaluation of this end point: 104 weeks
Secondary ID(s)
2017-000679-10-GB
CAIN457K2340
Source(s) of Monetary Support
Novartis Pharma AG
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 24/10/2018
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history